AASLD 2015: Gilead Leads Race To Shorter, Pan-Genotypic HCV Treatments
This article was originally published in Scrip
Executive Summary
Gilead Sciences has led the race to market with ribavirin- and interferon-free therapies that cure most people with the hepatitis C virus (HCV), but Merck & Co. Inc. is gaining ground in the sprint toward shorter-term, pan-genotypic, two- and three-drug regimens, with AbbVie Inc. on their heels with its own dual therapy that also may eliminate HCV infection in some of the most difficult to treat patients.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.